UNSPSC 51143013: Centrophenoxine or meclofenoxate

This classification denotes a neuroprotective agent and nootropic agent with the molecular formula C12H16ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C76QQ2I0RG, chemically known as acetic acid, (p-chlorophenoxy)-, 2-(dimethylamino)ethyl ester, hydrochloride but generally known as meclofenoxate, which bears US NIH Compound Identifier 4039. European Medicines Agency schedules Meclofenoxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08679MIG.

World Health Organization schedules meclofenoxate in its Anatomical Therapeutic Chemical (ATC) Classification. MECLOFENOXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CN(C)CCOC(=O)COC1=CC=C(C=C1)CL.

UNSPSC 51143013 Centrophenoxine or meclofenoxate is a Commodity code covering a specific pharmaceutical active ingredient used in nootropic and cognitive enhancement formulations. State and local governments procure this compound primarily through health department acquisitions, correctional facility medical services, and public hospital systems for use in authorized pharmaceutical manufacturing or compounding within their healthcare delivery operations. The ingredient itself is not a finished medication but rather a raw material or intermediate component that public health entities source for in-house preparation, clinical trial support, or procurement on behalf of contracted medical providers serving their populations.

The source provided contains no recent state and local contract opportunities tagged to this code. The lack of posted solicitations under UNSPSC 51143013 reflects the narrow and specialized nature of the commodity — centrophenoxine procurement is uncommon in state and local public procurement notice systems, as most health authorities acquire finished pharmaceutical products rather than raw active pharmaceutical ingredients, and when they do source such materials, procurement often occurs through existing group purchasing organization contracts, standing agreements with pharmaceutical wholesalers, or direct purchase orders that may not be published in public solicitation channels. Firms pursuing this code should monitor health department and hospital system RFPs for pharmaceutical manufacturing support contracts, which may reference ingredient sourcing as a subordinate line item.